{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:16:28Z","timestamp":1791472588411,"version":"4.3.4"},"reference-count":31,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients who develop steroid-refractory acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation have poor prognosis, highlighting an unmet therapeutic need. In this open-label phase 2 study (ClinicalTrials.gov identifier: NCT02953678), patients aged at least 12 years with grades II to IV steroid-refractory aGVHD were eligible to receive ruxolitinib orally, starting at 5 mg twice daily plus corticosteroids, until treatment failure, unacceptable toxicity, or death. The primary end point was overall response rate (ORR) at day 28; the key secondary end point was duration of response (DOR) at 6 months. As of 2 July 2018, 71 patients received at least 1 dose of ruxolitinib. Forty-eight of those patients (67.6%) had grade III\/IV aGVHD at enrollment. At day 28, 39 patients (54.9%; 95% confidence interval, 42.7%-66.8%) had an overall response, including 19 (26.8%) with complete responses. Best ORR at any time was 73.2% (complete response, 56.3%). Responses were observed across skin (61.1%), upper (45.5%) and lower (46.0%) gastrointestinal tract, and liver (26.7%). Median DOR was 345 days. Overall survival estimate at 6 months was 51.0%. At day 28, 24 (55.8%) of 43 patients receiving ruxolitinib and corticosteroids had a 50% or greater corticosteroid dose reduction from baseline. The most common treatment-emergent adverse events were anemia (64.8%), thrombocytopenia (62.0%), hypokalemia (49.3%), neutropenia (47.9%), and peripheral edema (45.1%). Ruxolitinib produced durable responses and encouraging survival compared with historical data in patients with steroid-refractory aGVHD who otherwise have dismal outcomes. The safety profile was consistent with expectations for ruxolitinib and this patient population.<\/jats:p>","DOI":"10.1182\/blood.2020004823","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T16:39:54Z","timestamp":1583944794000},"page":"1739-1749","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":285,"title":["Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial"],"prefix":"10.1182","volume":"135","author":[{"given":"Madan","family":"Jagasia","sequence":"first","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"first","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Schroeder","sequence":"first","affiliation":[{"name":"Section of Blood and Marrow Transplant, Division of Oncology, Department of Medicine, Washington University, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-7292","authenticated-orcid":false,"given":"Haris","family":"Ali","sequence":"first","affiliation":[{"name":"City of Hope, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav N.","family":"Shah","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bin","family":"Chen","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Fazal","sequence":"first","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fitzroy W.","family":"Dawkins","sequence":"first","affiliation":[{"name":"Incyte Corporation, Wilmington, DE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Arbushites","sequence":"first","affiliation":[{"name":"Incyte Corporation, Wilmington, DE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Tian","sequence":"first","affiliation":[{"name":"Incyte Corporation, Wilmington, DE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Connelly-Smith","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Howell","sequence":"first","affiliation":[{"name":"Incyte Corporation, Wilmington, DE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Jean","family":"Khoury","sequence":"first","affiliation":[{"name":"Winship Cancer Institute of Emory School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2020051411242955300_B1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nri3212","article-title":"Advances in graft-versus-host disease biology and therapy","volume":"12","author":"Blazar","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"2020051411242955300_B2","unstructured":"D\u2019Souza\n              A\n            , FrethamC. Current uses and outcomes of hematopoietic cell transplantation (HCT): 2018 summary slides. https:\/\/www.cibmtr.org\/ReferenceCenter\/SlidesReports\/SummarySlides\/_layouts\/15\/WopiFrame.aspx?sourcedoc=\/ReferenceCenter\/SlidesReports\/SummarySlides\/Documents\/2018%20Summary%20Slides%20-%20final%20-%20for%20web%20posting.pptx&action=default. Accessed 8 October 2019."},{"issue":"1","key":"2020051411242955300_B3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2020051411242955300_B4","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"issue":"22","key":"2020051411242955300_B5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020051411242955300_B6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbmt.2015.09.008","article-title":"Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors","volume":"22","author":"Lazaryan","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020051411242955300_B7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3324\/haematol.2013.093062","article-title":"Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease","volume":"99","author":"Inamoto","year":"2014","journal-title":"Haematologica"},{"issue":"8","key":"2020051411242955300_B8","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020051411242955300_B9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/bbmt.2002.v8.pm11939605","article-title":"Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment","volume":"8","author":"Arai","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020051411242955300_B10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbmt.2011.06.012","article-title":"Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment","volume":"18","author":"Xhaard","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020051411242955300_B11","unstructured":"Incyte Corporation\n          . FDA approves Jakafi\u00ae (ruxolitinib) for the treatment of patients with acute graft-versus-host disease [press release]. https:\/\/investor.incyte.com\/news-releases\/news-release-details\/fda-approves-jakafir-ruxolitinib-treatment-patients-acute-graft. Accessed 3 June 2019."},{"issue":"6","key":"2020051411242955300_B12","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.bbmt.2017.12.797","article-title":"The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia","volume":"24","author":"Schroeder","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020051411242955300_B13","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"issue":"24","key":"2020051411242955300_B14","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2020051411242955300_B15","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1182\/blood.V128.22.4561.4561","article-title":"Long-term follow-up of patients with corticosteroid-refractory graft-versus-host disease treated with ruxolitinib","volume":"128","author":"Zeiser","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020051411242955300_B16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020051411242955300_B17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.bbmt.2009.03.012","article-title":"Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement","volume":"15","author":"Martin","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020051411242955300_B18","unstructured":"Center for International Blood & Marrow Transplant Research (CIBMTR)\n          . Clinical trial endpoints for patients with acute GVHD. https:\/\/www.cibmtr.org\/Meetings\/Materials\/GVHDworkshop\/pages\/index.aspx. Accessed 1 February 2019."},{"issue":"3","key":"2020051411242955300_B19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020051411242955300_B20","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.bbmt.2013.04.018","article-title":"Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis","volume":"19","author":"Jagasia","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2020051411242955300_B21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood-2016-09-738625","article-title":"A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD","volume":"129","author":"Soci\u00e9","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020051411242955300_B22","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2017-11-815746","article-title":"\u03b11-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease","volume":"131","author":"Magenau","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2020051411242955300_B23","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bbmt.2009.05.019","article-title":"Infliximab for managing steroid-refractory acute graft-versus-host disease","volume":"15","author":"Pidala","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2020051411242955300_B24","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2017-03-772210","article-title":"Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease","volume":"129","author":"Chen","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020051411242955300_B25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000496809","article-title":"Clinical use of mesenchymal stromal cells in the treatment of acute graft-versus-host disease","volume":"46","author":"Elgaz","year":"2019","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"2020051411242955300_B26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/bmt.2016.225","article-title":"Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease","volume":"52","author":"Garc\u00eda-Cadenas","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020051411242955300_B27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.24572","article-title":"Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients","volume":"92","author":"Polverelli","year":"2017","journal-title":"Am J Hematol"},{"issue":"25","key":"2020051411242955300_B28","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"2020051411242955300_B29","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","article-title":"MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD","volume":"131","author":"Major-Monfried","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2020051411242955300_B30","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.bbmt.2018.11.013","article-title":"Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review","volume":"25","author":"Fl\u00f8isand","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020051411242955300_B31","article-title":"A phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease [published online ahead of print 7 September 2019]","author":"Kebriaei","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/20\/1739\/1728299\/bloodbld2020004823.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/20\/1739\/1728299\/bloodbld2020004823.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T04:38:41Z","timestamp":1589517521000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/20\/1739\/452638\/Ruxolitinib-for-the-treatment-of-steroidrefractory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":31,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2020,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020004823","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]}}}